These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 2766292)
1. Heterogeneity of glutathione content in human ovarian cancer. Lee FY; Vessey A; Rofstad E; Siemann DW; Sutherland RM Cancer Res; 1989 Oct; 49(19):5244-8. PubMed ID: 2766292 [TBL] [Abstract][Full Text] [Related]
2. Comparison of glutathione levels in rodent and human tumor cells grown in vitro and in vivo. Allalunis-Turner MJ; Lee FY; Siemann DW Cancer Res; 1988 Jul; 48(13):3657-60. PubMed ID: 3378208 [TBL] [Abstract][Full Text] [Related]
3. Sensitive enzymatic cycling assay for glutathione: measurements of glutathione content and its modulation by buthionine sulfoximine in vivo and in vitro in human colon cancer. Berger SJ; Gosky D; Zborowska E; Willson JK; Berger NA Cancer Res; 1994 Aug; 54(15):4077-83. PubMed ID: 8033140 [TBL] [Abstract][Full Text] [Related]
4. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system. Kolfschoten GM; Pinedo HM; Scheffer PG; Schlüper HM; Erkelens CA; Boven E Gynecol Oncol; 2000 Mar; 76(3):362-8. PubMed ID: 10684711 [TBL] [Abstract][Full Text] [Related]
5. Rapid development of drug resistance in human ovarian tumor xenografts after a single treatment with melphalan in Vivo. Caffrey PB; Zhang Y; Frenkel GD Anticancer Res; 1998; 18(4C):3021-5. PubMed ID: 9713503 [TBL] [Abstract][Full Text] [Related]
6. IFN-gamma induces apoptosis in ovarian cancer cells in vivo and in vitro. Wall L; Burke F; Barton C; Smyth J; Balkwill F Clin Cancer Res; 2003 Jul; 9(7):2487-96. PubMed ID: 12855622 [TBL] [Abstract][Full Text] [Related]
7. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors. Vanhoefer U; Cao S; Minderman H; Toth K; Skenderis BS; Slovak ML; Rustum YM Clin Cancer Res; 1996 Dec; 2(12):1961-8. PubMed ID: 9816155 [TBL] [Abstract][Full Text] [Related]
8. Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione. Geroni C; Marchini S; Cozzi P; Galliera E; Ragg E; Colombo T; Battaglia R; Howard M; D'Incalci M; Broggini M Cancer Res; 2002 Apr; 62(8):2332-6. PubMed ID: 11956092 [TBL] [Abstract][Full Text] [Related]
9. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143 [TBL] [Abstract][Full Text] [Related]
11. The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts. Goddard P; Valenti M; Kelland LR Anticancer Res; 1994; 14(3A):1065-70. PubMed ID: 8074451 [TBL] [Abstract][Full Text] [Related]
12. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression. Li D; Williams JI; Pietras RJ Oncogene; 2002 Apr; 21(18):2805-14. PubMed ID: 11973639 [TBL] [Abstract][Full Text] [Related]
13. Growth suppression of ovarian cancer xenografts in nude mice by vitamin D analogue EB1089. Zhang X; Jiang F; Li P; Li C; Ma Q; Nicosia SV; Bai W Clin Cancer Res; 2005 Jan; 11(1):323-8. PubMed ID: 15671562 [TBL] [Abstract][Full Text] [Related]
14. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454 [TBL] [Abstract][Full Text] [Related]
15. Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells. Mills GB; May C; Hill M; Campbell S; Shaw P; Marks A J Clin Invest; 1990 Sep; 86(3):851-5. PubMed ID: 2394835 [TBL] [Abstract][Full Text] [Related]
16. Cellular glutathione and thiol measurements from surgically resected human lung tumor and normal lung tissue. Cook JA; Pass HI; Iype SN; Friedman N; DeGraff W; Russo A; Mitchell JB Cancer Res; 1991 Aug; 51(16):4287-94. PubMed ID: 1868449 [TBL] [Abstract][Full Text] [Related]
17. A dominated and resistant subpopulation causes regrowth after response to 1,3-bis(2-chloroethyl)-1-nitrosourea treatment of a heterogeneous small cell lung cancer xenograft in nude mice. Aabo K; Roed H; Vindeløv LL; Spang-Thomsen M Cancer Res; 1994 Jun; 54(12):3295-9. PubMed ID: 8205552 [TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine. Cao S; McGuire JJ; Rustum YM Clin Cancer Res; 1999 Jul; 5(7):1925-34. PubMed ID: 10430100 [TBL] [Abstract][Full Text] [Related]
19. Inhibitory effect of bombesin receptor antagonist RC-3095 on the growth of human pancreatic cancer cells in vivo and in vitro. Qin Y; Ertl T; Cai RZ; Halmos G; Schally AV Cancer Res; 1994 Feb; 54(4):1035-41. PubMed ID: 8313359 [TBL] [Abstract][Full Text] [Related]
20. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Pegram MD; Finn RS; Arzoo K; Beryt M; Pietras RJ; Slamon DJ Oncogene; 1997 Jul; 15(5):537-47. PubMed ID: 9247307 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]